Yasir Al-Wakeel
Director/Board Member at MAXCYTE, INC.
Net worth: 449 933 $ as of 2024-03-30
Yasir Al-Wakeel active positions
| Companies | Position | Start | End |
|---|---|---|---|
| MAXCYTE, INC. | Director/Board Member | 2021-06-14 | - |
| Independent Dir/Board Member | 2021-06-14 | - |
Career history of Yasir Al-Wakeel
Former positions of Yasir Al-Wakeel
| Companies | Position | Start | End |
|---|---|---|---|
| KRONOS BIO, INC. | Comptroller/Controller/Auditor | 2020-07-31 | 2023-09-14 |
| Director of Finance/CFO | 2020-07-31 | 2023-09-14 | |
| NEON THERAPEUTICS, INC. | Director of Finance/CFO | 2017-05-31 | 2020-04-30 |
| MERRIMACK PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 2017-03-30 | 2017-06-30 |
| Director of Finance/CFO | 2015-08-03 | 2017-06-30 | |
| Treasurer | 2017-03-30 | 2017-06-30 | |
Credit Suisse Securities (Europe) Ltd.
 Credit Suisse Securities (Europe) Ltd. Investment ManagersFinance Credit Suisse Securities (Europe) Ltd. (Credit Suisse Europe) is the Great Britain-based brokerage subsidiary of Credit Suisse Investment Holdings (UK), itself a subsidiary of Credit Suisse Group AG (SWX: CSGN) in Switzerland. The firm was founded in 1966 and formerly known as Credit Suisse First Boston (Europe) Ltd. Headquartered in London, Credit Suisse Europe arranges financing in international capital markets, provides financial advisory services and acts as a dealer in securities, derivatives and foreign exchange on a principal and agency basis for corporate and institutional investors. | Analyst-Equity | 2008-03-31 | 2015-05-31 |
Training of Yasir Al-Wakeel
| University of Oxford | Doctorate Degree |
| University of Cambridge | Graduate Degree |
Statistics
International
| United States | 5 |
| United Kingdom | 4 |
Operational
| Director of Finance/CFO | 3 |
| Comptroller/Controller/Auditor | 2 |
| Analyst-Equity | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| MAXCYTE, INC. | Health Technology |
| MERRIMACK PHARMACEUTICALS, INC. | Health Technology |
| KRONOS BIO, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Credit Suisse Securities (Europe) Ltd.
Credit Suisse Securities (Europe) Ltd. Investment ManagersFinance Credit Suisse Securities (Europe) Ltd. (Credit Suisse Europe) is the Great Britain-based brokerage subsidiary of Credit Suisse Investment Holdings (UK), itself a subsidiary of Credit Suisse Group AG (SWX: CSGN) in Switzerland. The firm was founded in 1966 and formerly known as Credit Suisse First Boston (Europe) Ltd. Headquartered in London, Credit Suisse Europe arranges financing in international capital markets, provides financial advisory services and acts as a dealer in securities, derivatives and foreign exchange on a principal and agency basis for corporate and institutional investors. | Finance |
BioNTech US, Inc.
 BioNTech US, Inc. BiotechnologyHealth Technology BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Yasir Al-Wakeel
- Experience
